Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $75 to $90.
Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $75 to $90.